Colesevelam hydrochloride: A bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus

Prasanth N Surampudi, Prathima Nagireddy, Vivian A. Fonseca

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The complications of Type 2 diabetes mellitus (T2DM) include increased risk of macrovascular diseases such as coronary artery disease, stroke or peripheral vascular disease, and microvascular diseases such as retinopathy, neuropathy and nephropathy. The risk of macrovascular and microvascular diseases increases with the presence of dyslipidemia and hyperglycemia, respectively. Hence, treatment of T2DM must be aimed at treating hyperglycemia to prevent microvascular disease and dyslipidemia to prevent macrovascular complications. Recent clinical studies indicate that colesevelam hydrochloride, a bile acid sequestrant, appears to be promising as an add-on therapy for T2DM patients in reducing the hyperglycemia and dyslipidemia. The objective of the paper is to review the efficacy and safety of colesevelam hydrochloride in reducing both low-density lipid cholesterol and glycosylated hemoglobin A1c levels in T2DM patients when combined with metformin, sulfonylurea or insulin.

Original languageEnglish (US)
Pages (from-to)475-487
Number of pages13
JournalTherapy
Volume6
Issue number4
DOIs
StatePublished - Jul 2009
Externally publishedYes

Fingerprint

Dyslipidemias
Bile Acids and Salts
Type 2 Diabetes Mellitus
Hyperglycemia
Peripheral Vascular Diseases
Metformin
Glycosylated Hemoglobin A
Therapeutics
Coronary Artery Disease
Stroke
Cholesterol
Insulin
Lipids
Safety
Colesevelam Hydrochloride

Keywords

  • Bile acid sequestrants
  • Colesevelam HCl
  • Farnesoid X receptor
  • Glycemic control
  • Low-density lipoprotein cholesterol
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Colesevelam hydrochloride : A bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus. / Surampudi, Prasanth N; Nagireddy, Prathima; Fonseca, Vivian A.

In: Therapy, Vol. 6, No. 4, 07.2009, p. 475-487.

Research output: Contribution to journalReview article

@article{5398e58af4c3457595119a939230a059,
title = "Colesevelam hydrochloride: A bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus",
abstract = "The complications of Type 2 diabetes mellitus (T2DM) include increased risk of macrovascular diseases such as coronary artery disease, stroke or peripheral vascular disease, and microvascular diseases such as retinopathy, neuropathy and nephropathy. The risk of macrovascular and microvascular diseases increases with the presence of dyslipidemia and hyperglycemia, respectively. Hence, treatment of T2DM must be aimed at treating hyperglycemia to prevent microvascular disease and dyslipidemia to prevent macrovascular complications. Recent clinical studies indicate that colesevelam hydrochloride, a bile acid sequestrant, appears to be promising as an add-on therapy for T2DM patients in reducing the hyperglycemia and dyslipidemia. The objective of the paper is to review the efficacy and safety of colesevelam hydrochloride in reducing both low-density lipid cholesterol and glycosylated hemoglobin A1c levels in T2DM patients when combined with metformin, sulfonylurea or insulin.",
keywords = "Bile acid sequestrants, Colesevelam HCl, Farnesoid X receptor, Glycemic control, Low-density lipoprotein cholesterol, Type 2 diabetes mellitus",
author = "Surampudi, {Prasanth N} and Prathima Nagireddy and Fonseca, {Vivian A.}",
year = "2009",
month = "7",
doi = "10.2217/thy.09.17",
language = "English (US)",
volume = "6",
pages = "475--487",
journal = "Therapy",
issn = "2044-9038",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Colesevelam hydrochloride

T2 - A bile acid sequestrant for glycemic control and treatment of dyslipidemia in Type 2 diabetes mellitus

AU - Surampudi, Prasanth N

AU - Nagireddy, Prathima

AU - Fonseca, Vivian A.

PY - 2009/7

Y1 - 2009/7

N2 - The complications of Type 2 diabetes mellitus (T2DM) include increased risk of macrovascular diseases such as coronary artery disease, stroke or peripheral vascular disease, and microvascular diseases such as retinopathy, neuropathy and nephropathy. The risk of macrovascular and microvascular diseases increases with the presence of dyslipidemia and hyperglycemia, respectively. Hence, treatment of T2DM must be aimed at treating hyperglycemia to prevent microvascular disease and dyslipidemia to prevent macrovascular complications. Recent clinical studies indicate that colesevelam hydrochloride, a bile acid sequestrant, appears to be promising as an add-on therapy for T2DM patients in reducing the hyperglycemia and dyslipidemia. The objective of the paper is to review the efficacy and safety of colesevelam hydrochloride in reducing both low-density lipid cholesterol and glycosylated hemoglobin A1c levels in T2DM patients when combined with metformin, sulfonylurea or insulin.

AB - The complications of Type 2 diabetes mellitus (T2DM) include increased risk of macrovascular diseases such as coronary artery disease, stroke or peripheral vascular disease, and microvascular diseases such as retinopathy, neuropathy and nephropathy. The risk of macrovascular and microvascular diseases increases with the presence of dyslipidemia and hyperglycemia, respectively. Hence, treatment of T2DM must be aimed at treating hyperglycemia to prevent microvascular disease and dyslipidemia to prevent macrovascular complications. Recent clinical studies indicate that colesevelam hydrochloride, a bile acid sequestrant, appears to be promising as an add-on therapy for T2DM patients in reducing the hyperglycemia and dyslipidemia. The objective of the paper is to review the efficacy and safety of colesevelam hydrochloride in reducing both low-density lipid cholesterol and glycosylated hemoglobin A1c levels in T2DM patients when combined with metformin, sulfonylurea or insulin.

KW - Bile acid sequestrants

KW - Colesevelam HCl

KW - Farnesoid X receptor

KW - Glycemic control

KW - Low-density lipoprotein cholesterol

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=70449562097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449562097&partnerID=8YFLogxK

U2 - 10.2217/thy.09.17

DO - 10.2217/thy.09.17

M3 - Review article

AN - SCOPUS:70449562097

VL - 6

SP - 475

EP - 487

JO - Therapy

JF - Therapy

SN - 2044-9038

IS - 4

ER -